GALECTIN THERAPEUTICS INC
Developing galectin-3 inhibitors for MASH cirrhosis, fibrosis, and cancer.
GALT | NDAQ
Overview
Corporate Details
- ISIN(s):
- US3632252025
- LEI:
- Country:
- United States of America
- Address:
- 4960 PEACHTREE INDUSTRIAL BOULEVARD, 30071 NORCROSS
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops novel therapies for chronic liver disease, fibrosis, and cancer. The company's drug development programs are based on its expertise in galectin science, specifically targeting the galectin-3 protein, which is involved in numerous inflammatory, fibrotic, and malignant diseases. Its lead drug candidate is belapectin (GR-MD-02), a carbohydrate-based inhibitor of galectin-3. The company's primary development program is focused on treating non-alcoholic steatohepatitis (MASH) cirrhosis, a severe, life-threatening liver disease with no currently approved therapies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all GALECTIN THERAPEUTICS INC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for GALECTIN THERAPEUTICS INC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for GALECTIN THERAPEUTICS INC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
